In an article published in Health Policy and Planning, three Pharos staff and other collaborators from South Africa, Harvard, and Imperial College, and the Center for Disease Analysis present one of the first comprehensive investment cases for hepatitis scale-up in low and middle- income countries. In South Africa, Pharos supported the development of a five-year national strategy for hepatitis B and C, covering activities including hepatitis B birth dose vaccination, prevention of vertical transmission, treatment of hepatitis B, and treatment of hepatitis C with the new generation of highly-effective cures. The investment case synthesizes the expected cost, health impact, cost-effectiveness, and budget impact of this package of interventions. The paper finds that scale up of hepatitis investments could be both affordable and represent good value for money for South Africa, while averting thousands of new infections, deaths, and cases of advanced liver disease
In this commentary, Pharos President Robert Hecht and CSIS Global Health Policy Center Director Stephen Morrison explore a new and emerging paradigm for development assistance for health, in which middle income countries use domestic funding to pay for drugs, vaccines, health workers, and other inputs to disease control scale up, while donors focus their limited resources on key global public goods – knowledge and technical assistance that can help to shape and accelerate the design and implementation of life-saving interventions such as Hepatitis C treatment.